Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Int J Cancer
    July 2026
  1. FAN X, Wei C, Rong M, Wang S, et al
    Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors.
    Int J Cancer. 2026;159:269-279.
    >> Share

    June 2026
  2. JIN H, Huang H, Wu Y, Zhang Y, et al
    Efficacy of first-line immunochemotherapy across KRAS mutation subtypes in advanced lung adenocarcinoma.
    Int J Cancer. 2026;158:3187-3196.
    >> Share

  3. VANSTRAELEN S, Reiner A, Tan KS, Mastrogiacomo B, et al
    Somatic copy number variation as a prognostic marker for recurrence in never-smokers with early-stage lung adenocarcinoma.
    Int J Cancer. 2026;158:2900-2911.
    >> Share

  4. HAFEEZ KS, Debernardi C, Allione A, Herman EJ, et al
    Integrating polygenic and methylation risk scores for pleural mesothelioma risk stratification.
    Int J Cancer. 2026;158:2866-2879.
    >> Share

    May 2026
  5. DIVER WR, Teras LR, Deubler EL, Patel AV, et al
    Associations of Outdoor Air Pollution With Incidence of Cancers Other Than Lung Cancer in a Large US Prospective Cohort.
    Int J Cancer. 2026 May 3. doi: 10.1002/ijc.70530.
    >> Share

    April 2026
  6. NIEDERMAIER B, Bochtler T, Eichhorn F, Griffo R, et al
    Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.
    Int J Cancer. 2026 Apr 19. doi: 10.1002/ijc.70508.
    >> Share

  7. TIAN Z, Dai S, Yang X, Zou B, et al
    Thoracic radiotherapy synergizes with first-line EGFR-TKIs in advanced EGFR-mutant NSCLC: A dual-center real-world study.
    Int J Cancer. 2026;158:2168-2178.
    >> Share

  8. WANG J, Song P, Ge Y, Yang H, et al
    Effect of Interval Between Neoadjuvant Immunochemotherapy and Radical Resection of Non-Small Cell Lung Cancer: A Multicenter, Retrospective Cohort Study.
    Int J Cancer. 2026 Apr 9. doi: 10.1002/ijc.70473.
    >> Share

  9. KOTO R, Yamamoto A, Takashima I, Iwao C, et al
    Survival by Detection Pathway in Patients With Lung Cancer-A Nationwide Descriptive Epidemiological Study in Japan.
    Int J Cancer. 2026 Apr 8. doi: 10.1002/ijc.70474.
    >> Share

  10. MOU B, Duan Y, Wang J, Li T, et al
    Genomic signature driving preinvasive to invasive processes in stage I lung adenocarcinoma.
    Int J Cancer. 2026;158:1975-1988.
    >> Share

    March 2026
  11. ACKER F, Wenger K, Reck M, Waller CF, et al
    Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315).
    Int J Cancer. 2026 Mar 23. doi: 10.1002/ijc.70456.
    >> Share

  12. TANG W, Hou X, Li L, Zhao H, et al
    Coronavirus disease 2019 infection reduces EGFR-TKI efficacy in non-small cell lung carcinoma: Real-world evidence from a multicenter propensity-matched cohort.
    Int J Cancer. 2026 Mar 20. doi: 10.1002/ijc.70444.
    >> Share

  13. TSURUTA A, Fujimoto M, Hiraoka Y, Taniguchi A, et al
    C-X-C chemokine receptor CXCR4 mediates diurnal changes in the aggregation and dispersion of CD8(+) T cells within the tumor microenvironment.
    Int J Cancer. 2026;158:1740-1754.
    >> Share

  14. WANG D, Liu T, Yin B, Chang Y, et al
    The lung pre-metastatic niche in osteosarcoma: Mechanism and therapeutic intervention.
    Int J Cancer. 2026;158:1450-1463.
    >> Share

  15. JIN D, Zhong L, Chen L
    Lung cancer as a global health challenge: Multidimensional biomarker research and therapeutic advances.
    Int J Cancer. 2026 Mar 13. doi: 10.1002/ijc.70419.
    >> Share

  16. PARK S, Kang D, Lee J, Jung HA, et al
    Treatment patterns and clinical outcomes in real-world patients with small-cell lung cancer in South Korea: A single-center experience.
    Int J Cancer. 2026 Mar 13. doi: 10.1002/ijc.70449.
    >> Share

  17. HUANG P, Song J, Liu J, Li Y, et al
    Clinicopathological and genomic features of early-onset non-small cell lung cancer across age and ethnicity.
    Int J Cancer. 2026 Mar 7. doi: 10.1002/ijc.70425.
    >> Share

    February 2026
  18. NEOGI U, Ambikan AT, Turkowski K, Schneider MA, et al
    Plasma proteomic profiling and molecular clustering reveal immune-defined prognostic subtypes in lung adenocarcinoma.
    Int J Cancer. 2026;158:858-865.
    >> Share

  19. XU M, Xu Y, Man Y, Xiang X, et al
    Real-world effectiveness and safety of treatment strategies for unresectable, driver-negative Stage III NSCLC: A retrospective multicentre study.
    Int J Cancer. 2026;158:1042-1054.
    >> Share

  20. LI W, Ge Y, Zhang Z, Gan J, et al
    Construction and immunotherapy application of lung cancer organoids.
    Int J Cancer. 2026 Feb 12. doi: 10.1002/ijc.70347.
    >> Share

    January 2026
  21. WANG A, Wang S, Zhang S, Liu F, et al
    Discovery of biomarkers in the era of radioimmunotherapy against lung cancer: A bench-to-bedside promise.
    Int J Cancer. 2026 Jan 28. doi: 10.1002/ijc.70352.
    >> Share

  22. MAYURI M, Reddy Kandula S, Ramakrishna V, Sanka P, et al
    Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.
    Int J Cancer. 2026 Jan 2. doi: 10.1002/ijc.70318.
    >> Share

  23. LIANG XL, Su YD, Fu YB, Yu Y, et al
    Efficacy of postoperative immunotherapy on MPM patients after CRS + HIPEC: A single-center retrospective study based on propensity score matching.
    Int J Cancer. 2026;158:232-242.
    >> Share

  24. WU J, Mo A, Zhuang W, Chen R, et al
    Distinctive clinical and radiological characteristics of persistent super-multiple ground-glass pulmonary nodules.
    Int J Cancer. 2026;158:60-68.
    >> Share

  25. ZENG C, Tan Y, Jiao Z, Hu S, et al
    A multicenter randomized controlled trial of intrapleural perfusion of methotrexate-loaded tumor cell-derived microparticles combined with systemic therapy for malignant pleural effusion.
    Int J Cancer. 2026;158:172-181.
    >> Share

    December 2025
  26. WU YL, Zhang L, Fan Y, Zhou J, et al
    Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score >/=1%: KEYNOTE-042 China study.
    Int J Cancer. 2025 Dec 31. doi: 10.1002/ijc.70265.
    >> Share

  27. WU YS, Kunst N, Gyorbiro DM, Kristiansen IS, et al
    Cost-effectiveness of low-dose CT lung cancer screening among individuals that have ever smoked in Norway: A model-based analysis using NELSON trial criteria and outcomes.
    Int J Cancer. 2025 Dec 19. doi: 10.1002/ijc.70270.
    >> Share

  28. SU J, Hua J, Fan X, Wan X, et al
    Associations of diabetes status, duration, and onset age with the risk of lung cancer: Results from the China Kadoorie Biobank study.
    Int J Cancer. 2025 Dec 12. doi: 10.1002/ijc.70294.
    >> Share

    November 2025
  29. CABRERA MO, Ten Haaf K, Borras JM, Font R, et al
    Impact of lung cancer screening eligibility criteria on participants' characteristics and healthcare resources.
    Int J Cancer. 2025 Nov 24. doi: 10.1002/ijc.70263.
    >> Share

  30. MO H, Zhang Y, Tian Z, Yue P, et al
    Induction chemoimmunotherapy followed by radiotherapy and consolidation immunotherapy versus definitive concurrent chemoradiotherapy with consolidation immunotherapy for unresectable stage III non-small cell lung cancer: A single-center retrospective
    Int J Cancer. 2025 Nov 7. doi: 10.1002/ijc.70238.
    >> Share

  31. EIJKELBOOM AH, d'Hooghe JNS, van der Sangen M, van den Heuvel MM, et al
    Income inequalities, tumor stage at diagnosis, and treatment in patients with non-small cell lung cancer: A population-based study in the Netherlands.
    Int J Cancer. 2025 Nov 7. doi: 10.1002/ijc.70230.
    >> Share

  32. YU S, Li H, Lu H, Huang Z, et al
    Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive-stage small-cell lung cancer: Results of two prospective phase II studies.
    Int J Cancer. 2025 Nov 6. doi: 10.1002/ijc.70224.
    >> Share

    October 2025
  33. TAKAMORI S, Shimokawa M, Yamaguchi M, Mori M, et al
    Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non-small cell lung cancer.
    Int J Cancer. 2025 Oct 26. doi: 10.1002/ijc.70170.
    >> Share

  34. EFIL SC, Ozsan Celebi SN, Ozturk B, Bilgin B, et al
    Synergistic prognostic effect of the renin-angiotensin-aldosterone system and immune-checkpoint inhibition in advanced lung cancer: The SPERICIL study.
    Int J Cancer. 2025 Oct 4. doi: 10.1002/ijc.70169.
    >> Share

    September 2025
  35. YOSHIKAWA R, Watanabe T, Ohtaki Y, Bando T, et al
    Novel therapeutic strategy targeting STMN1 using chlorambucil-conjugated pyrrole-imidazole polyamide in small cell lung cancer.
    Int J Cancer. 2025 Sep 30. doi: 10.1002/ijc.70179.
    >> Share

  36. ZHAO Z, Rong H, Li M, Xu Y, et al
    Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited-stage small-cell lung cancer: A retrospective, multi-center, real-world study.
    Int J Cancer. 2025 Sep 13. doi: 10.1002/ijc.70153.
    >> Share

  37. XU Y, Zhang Q, Gao J, Yao S, et al
    Effects of immune checkpoint inhibitors on the pulmonary circulation in lung cancer patients.
    Int J Cancer. 2025 Sep 5. doi: 10.1002/ijc.70110.
    >> Share

  38. BRITO-ROCHA T, Constancio V, Leite-Silva P, Carvalho-Maia C, et al
    Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test.
    Int J Cancer. 2025;157:1006-1019.
    >> Share

  39. SUN Y, Deng Z, Sun H, Wei X, et al
    Prognostic impact of the timing of immunotherapy in first-line immunochemotherapy for patients with advanced lung adenocarcinoma: A propensity score-matched analysis.
    Int J Cancer. 2025;157:916-926.
    >> Share

  40. KANNO C, Kojima M, Watanabe Y, Honda R, et al
    Molecular targeted drugs affect the development of antiresorptive-related osteonecrosis of the jaw in patients with lung and kidney cancers.
    Int J Cancer. 2025;157:890-896.
    >> Share

  41. CHEN T, Wang W, Qian Y, Wang M, et al
    Immune checkpoint inhibitors combined with anti-angiogenic therapy as second- or further-line treatment for small cell lung cancer: Efficacy, safety, and prognostic biomarkers.
    Int J Cancer. 2025 Sep 1. doi: 10.1002/ijc.70102.
    >> Share

    August 2025
  42. ZHANG Q, Fu Q, Hou Y, Lv Y, et al
    Advances in CAR-T therapy for small cell lung cancer.
    Int J Cancer. 2025 Aug 18. doi: 10.1002/ijc.70093.
    >> Share

  43. LI W, Pan S, Qian J, Xia Y, et al
    Comparisons of blood, upper respiratory tract and gut viromes from patients with lung cancer and healthy persons.
    Int J Cancer. 2025 Aug 8. doi: 10.1002/ijc.70075.
    >> Share

  44. ZHONG R, Chu T, Xiong L, Shi C, et al
    Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: A phase II study.
    Int J Cancer. 2025;157:549-558.
    >> Share

    July 2025
  45. DE VRIES F, Otten LS, Piet B, Franssen EJF, et al
    Early pembrolizumab clearance as prognostic biomarker for non-response in patients with advanced non-small cell lung cancer.
    Int J Cancer. 2025 Jul 24. doi: 10.1002/ijc.70052.
    >> Share

  46. DU Y, Yuan C, Ni X, Miao J, et al
    Overdiagnosis in low-dose CT lung cancer screening: A systematic review and meta-analysis of overall magnitude and subgroup variations.
    Int J Cancer. 2025 Jul 18. doi: 10.1002/ijc.70049.
    >> Share

  47. DE NIJS K, Ten Haaf K, Hubert J, Moldovanu D, et al
    Stage- and histology-specific sensitivity for the detection of lung cancer of the NELSON screening protocol-A modeling study.
    Int J Cancer. 2025 Jul 11. doi: 10.1002/ijc.70045.
    >> Share

  48. DENG Y, Guo C, Zhang T, Chen Y, et al
    Comprehensive analysis of a real-world cohort identifies geranylgeranyl diphosphate synthase 1 as a predictor of chemoresistance in small cell lung cancer.
    Int J Cancer. 2025 Jul 4. doi: 10.1002/ijc.70036.
    >> Share

    June 2025
  49. WANG K, Xiang J, Zhou J, Chen C, et al
    Development and validation of a transcription factor regulatory network-based signature for individualized prognostic risk in lung adenocarcinoma.
    Int J Cancer. 2025;156:2440-2451.
    >> Share

  50. CHANG GC, Kapoor A, Lee CK, Su C, et al
    Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia: An expert opinion.
    Int J Cancer. 2025 Jun 14. doi: 10.1002/ijc.35512.
    >> Share

  51. ZHAO R, Lu H, Yuan H, Chen S, et al
    Plasma proteomic profiles for early detection and risk stratification of non-small cell lung carcinoma: A prospective cohort study with 52,913 participants.
    Int J Cancer. 2025 Jun 6. doi: 10.1002/ijc.35518.
    >> Share

    April 2025
  52. XIE Y, Fang H, Cheng W, Xu T, et al
    Furmonertinib in uncommon EGFR-mutated non-small cell lung cancer with central nervous system metastases: A retrospective cohort study.
    Int J Cancer. 2025 Apr 29. doi: 10.1002/ijc.35460.
    >> Share

  53. TSURUDA KM, Hektoen HH, Aamelfot C, Andreassen BK, et al
    Let's talk about sex: Survival among females and males in a real-world cohort treated with pembrolizumab for non-small cell lung cancer.
    Int J Cancer. 2025 Apr 29. doi: 10.1002/ijc.35445.
    >> Share

  54. NOFAL S, J Ostrin E, Zhang J, Wu J, et al
    Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility status.
    Int J Cancer. 2025 Apr 18. doi: 10.1002/ijc.35452.
    >> Share

  55. DIAO M, Wang Y, Wu S, He S, et al
    Estrogen, estrogen receptor and the tumor microenvironment of NSCLC.
    Int J Cancer. 2025;156:1501-1508.
    >> Share

  56. NOMURA K, Takada K, Kinoshita F, Muto S, et al
    Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study).
    Int J Cancer. 2025;156:1480-1491.
    >> Share

    March 2025
  57. HEMMINKI K, Zitricky F, Sundquist K, Sundquist J, et al
    Sex specific familial risk in lung cancer through changing histologies in Sweden.
    Int J Cancer. 2025 Mar 29. doi: 10.1002/ijc.35431.
    >> Share

    February 2025
  58. XU H, Fu X, Wang S, Ge Y, et al
    Immunoglobulin-like transcript 5 polarizes M2-like tumor-associated macrophages for immunosuppression in non-small cell lung cancer.
    Int J Cancer. 2025 Feb 5. doi: 10.1002/ijc.35360.
    >> Share

    January 2025
  59. NALWOGA A, Jackson C, Fiorillo S, Manyeruke F, et al
    Evaluation of plasma alpha-1-antichymotrypsin as a marker for pulmonary Kaposi sarcoma.
    Int J Cancer. 2025 Jan 30. doi: 10.1002/ijc.35351.
    >> Share

  60. KANZAKI R, Reid S, Bolivar P, Sjolund J, et al
    FHL2 expression by cancer-associated fibroblasts promotes metastasis and angiogenesis in lung adenocarcinoma.
    Int J Cancer. 2025;156:431-446.
    >> Share

  61. LAZZARI N, Rigotto G, Montini B, Del Bianco P, et al
    Stemness and hybrid epithelial-mesenchymal profiles guide peritoneal dissemination of malignant mesothelioma and pseudomyxoma peritonei.
    Int J Cancer. 2025;156:201-215.
    >> Share

    December 2024
  62. CHEI CL, Nakamura S, Watanabe K, Mizutani T, et al
    Assessing the performance of chest x-ray screening in detecting early-stage lung cancer in the general population.
    Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35316.
    >> Share

  63. LU G, Liu H, Wang H, Luo S, et al
    Genetic variants of FER and SULF1 in the fibroblast-related genes are associated with non-small-cell lung cancer survival.
    Int J Cancer. 2024 Dec 20. doi: 10.1002/ijc.35305.
    >> Share

  64. YANG ZM, Qin XY, Lu YY, Yao LK, et al
    Pathogen spectrum and clinical characteristics of lung cancer patients: A 10-year retrospective study.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35272.
    >> Share

  65. BRANCO H, Rodrigues CA, Oliveira J, Mendes N, et al
    Preclinical studies on the antitumor and non-toxic effect of combining pirfenidone with vinorelbine and carboplatin in non-small cell lung cancer.
    Int J Cancer. 2024 Dec 4. doi: 10.1002/ijc.35276.
    >> Share

    November 2024
  66. BURUS T, Patel MI, Christian WJ, Huang B, et al
    Sex-based differences in histologic lung cancer incidence trends in the United States, 2005-2019.
    Int J Cancer. 2024 Nov 21. doi: 10.1002/ijc.35268.
    >> Share

  67. JIANG C, Freedman RA, Punglia RS, Jemal A, et al
    Associations of radiotherapy receipt with lung cancer risk by histological subtype among breast cancer survivors in the United States.
    Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35257.
    >> Share

  68. TAKADA K, Takamori S, Shimokawa M, Pinato DJ, et al
    Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35249.
    >> Share

    October 2024
  69. JEMAL A, Schafer EJ, Star J, Bandi P, et al
    Lung cancer incidence rates in young women and men by state in the United States.
    Int J Cancer. 2024 Oct 11. doi: 10.1002/ijc.35188.
    >> Share

  70. MA Z, Zhu Z, Pang G, Gong F, et al
    Development and validation of a lung cancer polygenic risk score incorporating susceptibility variants for risk factors.
    Int J Cancer. 2024 Oct 8. doi: 10.1002/ijc.35210.
    >> Share

  71. KISHIDA R, Yin X, Abe SK, Rahman MS, et al
    Association between family history with lung cancer incidence and mortality risk in the Asia Cohort Consortium.
    Int J Cancer. 2024 Oct 3. doi: 10.1002/ijc.35191.
    >> Share

    September 2024
  72. HU H, Zhu Q, Tang H, Zhang SC, et al
    The risk of treatment-related toxicities with PD-1/PD-L1 inhibitors in patients with lung cancer.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35195.
    >> Share

  73. WANG H, Liu H, Tang X, Lu G, et al
    Potentially functional variants of PARK7 and DDR2 in ferroptosis-related genes predict survival of non-small cell lung cancer patients.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35197.
    >> Share

  74. WIESWEG M, Kuter C, Schnorbach J, Keyl J, et al
    Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35199.
    >> Share

    August 2024
  75. SCHULTE C, Gauler T, Pottgen C, Friedel G, et al
    Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE).
    Int J Cancer. 2024 Aug 28. doi: 10.1002/ijc.35131.
    >> Share

  76. CHEN S, Cheng S, Cai J, Liu Z, et al
    The current therapeutic cancer vaccines landscape in non-small cell lung cancer.
    Int J Cancer. 2024 Aug 7. doi: 10.1002/ijc.35088.
    >> Share

    July 2024
  77. PULAWSKA-MOON K, Ponikwicka-Tyszko D, Lebiedzinska W, Pilaszewicz-Puza A, et al
    Novel ectopic expression of zona pellucida 3 glycoprotein in lung cancer promotes tumor growth.
    Int J Cancer. 2024 Jul 22. doi: 10.1002/ijc.35098.
    >> Share

  78. BRATIVNYK A, Ankill J, Helland A, Fleischer T, et al
    Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma.
    Int J Cancer. 2024;155:282-297.
    >> Share

  79. YIN M, Liu L, Yan Y, Wang H, et al
    A targeting nanoplatform for chemo-photothermal synergistic therapy of small-cell lung cancer.
    Int J Cancer. 2024 Jul 10. doi: 10.1002/ijc.35065.
    >> Share

  80. ZHANG Q, Chen K, Yu X, Fan Y, et al
    Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.
    Int J Cancer. 2024 Jul 3. doi: 10.1002/ijc.35070.
    >> Share

    June 2024
  81. MELOSKY B, Vincent MD, McGuire AL, Brade AM, et al
    Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancer.
    Int J Cancer. 2024 Jun 20. doi: 10.1002/ijc.35031.
    >> Share

  82. ZHANG B, Li C, Wu J, Zhang J, et al
    DeepCG: A cell graph model for predicting prognosis in lung adenocarcinoma.
    Int J Cancer. 2024;154:2151-2161.
    >> Share

  83. CHEN C, Zhou X, Gao X, Pan R, et al
    Immune responses and reinfection of SARS-CoV-2 Omicron variant in patients with lung cancer.
    Int J Cancer. 2024 Jun 5. doi: 10.1002/ijc.35038.
    >> Share

  84. GU Z, Huang P, Zhao J, Luo C, et al
    Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs.
    Int J Cancer. 2024;154:1979-1986.
    >> Share

  85. SEBASTIAN M, Eberhardt WEE, von der Heyde E, Dorfel S, et al
    Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315).
    Int J Cancer. 2024;154:1967-1978.
    >> Share

    May 2024
  86. MIYAMORI D, Kamitani T, Yoshida S, Kikuchi Y, et al
    Effects of the Coronavirus disease 2019 pandemic on mortality in patients with lung cancer: A multiple mediation analysis in Japan.
    Int J Cancer. 2024 May 24. doi: 10.1002/ijc.35042.
    >> Share

  87. WANG Z, Zhang Q, Wang C, Herth FJF, et al
    Multiple primary lung cancer: Updates and perspectives.
    Int J Cancer. 2024 May 23. doi: 10.1002/ijc.34994.
    >> Share

  88. KOURO T, Higashijima N, Horaguchi S, Mano Y, et al
    Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1.
    Int J Cancer. 2024;154:1828-1841.
    >> Share

    April 2024
  89. RAHMAN ML, Shu XO, Jones DP, Hu W, et al
    A nested case-control study of untargeted plasma metabolomics and lung cancer among never-smoking women within the prospective Shanghai Women's Health Study.
    Int J Cancer. 2024 Apr 23. doi: 10.1002/ijc.34929.
    >> Share

  90. MULSHINE JL, Avila RS, Rizzo AA, Estepar RSJ, et al
    Quantitative imaging workshop XIX: Utilizing quantitative thoracic imaging to optimize population health final summary.
    Int J Cancer. 2024;154:1365-1370.
    >> Share

    March 2024
  91. LIU X, Xie X, Sui C, Liu X, et al
    Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: Mechanisms and clinical implications.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34900.
    >> Share

    February 2024
  92. YIN X, Kishida R, Abe SK, Islam MR, et al
    Association between reproductive factors with lung cancer incidence and mortality: A pooled analysis of over 308,000 females in the Asia cohort consortium.
    Int J Cancer. 2024 Feb 20. doi: 10.1002/ijc.34866.
    >> Share

  93. WELSCH E, Holzer B, Schuster E, Fabikan H, et al
    Prognostic significance of circulating tumor cells and tumor related transcripts in small cell lung cancer: A step further to clinical implementation.
    Int J Cancer. 2024 Feb 14. doi: 10.1002/ijc.34886.
    >> Share

    January 2024
  94. MORITA A, Ichihara E, Inoue K, Fujiwara K, et al
    Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
    Int J Cancer. 2024 Jan 9. doi: 10.1002/ijc.34842.
    >> Share

  95. ZAHED H, Feng X, Sheikh M, Bray F, et al
    Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
    Int J Cancer. 2024;154:28-40.
    >> Share

  96. KEMMOTSU N, Ninomiya K, Kunimasa K, Ishino T, et al
    Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies.
    Int J Cancer. 2024;154:169-179.
    >> Share

    December 2023
  97. MORISUE R, Kojima M, Suzuki T, Watanabe R, et al
    Common clinicopathological and immunological features of sarcomatoid carcinoma across organs: A histomorphology-based cross-organ study.
    Int J Cancer. 2023;153:1997-2010.
    >> Share

    November 2023
  98. JANSEN L, Schwettmann L, Behr C, Eberle A, et al
    Trends in cancer incidence by socioeconomic deprivation in Germany in 2007 to 2018: An ecological registry-based study.
    Int J Cancer. 2023;153:1784-1796.
    >> Share

  99. PELOS G, Riester M, Pal J, Myacheva K, et al
    Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment.
    Int J Cancer. 2023 Nov 10. doi: 10.1002/ijc.34783.
    >> Share

    October 2023
  100. YU Z, Dong X, Song M, Xu A, et al
    Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.
    Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34769.
    >> Share

  101. WEI X, Sun D, Gao J, Zhang J, et al
    Development and evaluation of a polygenic risk score for lung cancer in never-smoking women: A large-scale prospective Chinese cohort study.
    Int J Cancer. 2023 Oct 17. doi: 10.1002/ijc.34765.
    >> Share

  102. VAN VEELEN A, Veerman GDM, Verschueren MV, Gulikers JL, et al
    Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.
    Int J Cancer. 2023 Oct 15. doi: 10.1002/ijc.34742.
    >> Share

  103. YU Z, Ni P, Yu H, Zuo T, et al
    Effectiveness of a single low-dose computed tomography screening for lung cancer: A population-based perspective cohort study in China.
    Int J Cancer. 2023 Oct 11. doi: 10.1002/ijc.34741.
    >> Share

  104. TOMONAGA Y, de Nijs K, Bucher HC, de Koning H, et al
    Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in Switzerland.
    Int J Cancer. 2023 Oct 4. doi: 10.1002/ijc.34746.
    >> Share

    September 2023
  105. SJODAHL G, Eriksson P, Holmsten K, Abrahamsson J, et al
    Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer.
    Int J Cancer. 2023 Sep 6. doi: 10.1002/ijc.34715.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016